OVERVIEW OF ACTIVITY
The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. This unique conference provides many clinicians and scientists from around the world a forum for discussing critical issues in the prevention and management of breast cancer. Therefore, SABCS is targeted by many members of the clinical research community as the optimal time to unveil new clinical data. This creates an environment in which yearly published results from a plethora of ongoing clinical trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes.
Although SABCS currently offers online access to the vast majority of the poster and plenary presentations from the annual meeting, the absence of expert assessment concerning practical applications may yield confusion among community oncologists who are challenged almost daily to appropriately apply a multitude of scientific findings across diverse tumors. Thus, identification of those data sets with immediate or impending relevance to the delivery of quality breast cancer care, in conjunction with professional commentary to address resultant practice ambiguity, may prove vastly beneficial to those physicians who are unable to make the annual pilgrimage to San Antonio. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS, including expert perspectives on how these new evidence-based concepts can and should be incorporated into on- and off-protocol patient care. This activity will assist medical oncologists, radiation oncologists, breast/general surgeons, nurses and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.
LEARNING OBJECTIVES
Please see individual web programs for CME program-specific information.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Please see individual web programs for CME program-specific information.
HOW TO USE THIS CME ACTIVITY
Please see individual web programs for CME program-specific information.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Please see individual web programs for CME program-specific information.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Eisai Inc, Genentech BioOncology and Genomic Health Inc.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: January/February/March/April/May 2013
Expiration date: January/February/March/April/May 2014
Overview This 5-part web program is part of an email series designed for dedicated but frenzied oncology professionals attempting to keep up with an exploding clinical research database. Subscribers to this program receive weekly emails that include links to slides from important data sets presented at SABCS 2012 along with brief comments from clinical investigators about the significance of these results. Current Issue
Read Dr Love’s original email (May 9, 2013)
Efficacy and Optimal Duration of Trastuzumab Combined with Adjuvant Chemotherapy and Genetic Predictors of Response to HER2-Targeted Therapy in Patients with Early HER2-Positive Breast Cancer
Program Description: A summary of updated research data evaluating 1 year versus 6 months or 2 years of adjuvant trastuzumab and the efficacy of trastuzumab in combination with adjuvant chemotherapy in patients enrolled in the NSABP-B-31 and NCCTG-N9831 trials. Results of a genetic analysis of patient samples from the NeoSphere study in an effort to identify predictors of response to HER2-targeted therapy are also presented.
Full Abstracts:
HERA: 2 Years versus 1 Year of Adjuvant Trastuzumab at 8 Years of Follow-Up
Goldhirsch A et al. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. San Antonio Breast Cancer Symposium 2012; Abstract S5-2.
PHARE: 6 Months versus 12 Months of Adjuvant Trastuzumab
Pivot X et al. PHARE trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. San Antonio Breast Cancer Symposium 2012; Abstract S5-3.
Final Planned Joint Analysis of Overall Survival from NSABP-B-31 and NCCTG-N9831
Romond E et al. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. San Antonio Breast Cancer Symposium 2012; Abstract S5-5.
Association between the Adaptive Immune System and Immune Checkpoints and Response to Pertuzumab and Trastuzumab
Gianni L et al. Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere study. San Antonio Breast Cancer Symposium 2012; Abstract S6-7.
Issue 4 — April 25, 2013
Read Dr Love’s original email (April 25, 2013)
Chemotherapeutic Treatment of Early Triple-Negative Breast Cancer and Locally Advanced/Metastatic Breast Cancer
Program Description: A summary of research data evaluating the efficacy and safety of combination or single-agent chemotherapy for patients with early triple-negative or locally advanced/metastatic breast cancer.
Full Abstracts:
CALOR Trial of Adjuvant Chemotherapy for Local or Regional Recurrence of Breast Cancer
Aebi S et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). San Antonio Breast Cancer Symposium 2012; Abstract S3-2.
A Phase III Trial of Eribulin Mesylate versus Capecitabine for Locally Advanced or Metastatic Breast Cancer
Kaufman PA et al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. San Antonio Breast Cancer Symposium 2012; Abstract S6-6.
A Phase II Study of First-Line Eribulin Mesylate for Locally Recurrent or Metastatic HER2-Negative Breast Cancer
Vahdat L et al. Results of a Phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer. San Antonio Breast Cancer Symposium 2012; Abstract P1-12-02.
BEATRICE Trial Evaluating the Addition of Bevacizumab to Adjuvant Chemotherapy for Triple-Negative Breast Cancer
Cameron D et al. Primary results of BEATRICE, a randomized Phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. San Antonio Breast Cancer Symposium 2012; Abstract S6-5.
Issue 3 — April 2, 2013
Read Dr Love’s original email (April 2, 2013)
Biomarkers and Genomic Signature Assays to Predict Therapeutic Response or Disease Recurrence in Lymph Node-Positive or Negative and Estrogen Receptor-Positive Breast Cancer and Variability in Reporting of Ki-67 IHC Assay Results
Program Description: A summary of research data evaluating the accuracy of biomarkers and genomic signature assays in predicting treatment response, disease recurrence or late distant metastases for patients with estrogen receptor-positive breast cancer. Results from an international study evaluating concordance among laboratories in the analysis and scoring of Ki-67 by IHC assay is also presented.
Full Abstracts:
Association between the 21-Gene Recurrence Score and Benefit from Adjuvant Paclitaxel in Node-Positive, ER-Positive Breast Cancer
Mamounas EP et al. Association between the 21-gene Recurrence Score (RS) and benefit from addition of adjuvant paclitaxel in node-positive, ER-positive breast cancer patients: Results from NSABP B-28. San Antonio Breast Cancer Symposium 2012; Abstract S1-10.
The EndoPredict Score Identifies Late Distant Metastases in ER-Positive, HER2-Negative Breast Cancer
Dubsky P et al. The EndoPredict score identifies late distant metastases in ER+/HER2- breast cancer patients. San Antonio Breast Cancer Symposium 2012; Abstract S4-3.
Performance of the Breast Cancer Index versus Oncotype DX Recurrence Score and IHC4 in Predicting Late Recurrence of Breast Cancer
Sgroi DC et al. Comparative performance of Breast Cancer Index (BCI) vs Oncotype Dx and IHC4 in the prediction of late recurrence in HR-positive, LN-negative breast cancer patients: A TransATAC study. San Antonio Breast Cancer Symposium 2012; Abstract S1-9.
An International Ki-67 Reproducibility Study
Nielsen TO et al. An international Ki67 reproducibility study. San Antonio Breast Cancer Symposium 2012; Abstract S4-6.
Metabolic Syndrome and Recurrence According to the 21-Gene Recurrence Score in Node-Negative Breast Cancer
Lakhani A et al. Metabolic syndrome and recurrence within the 21-gene Recurrence Score assay risk categories in lymph node negative breast cancer. San Antonio Breast Cancer Symposium 2012; Abstract PD10-02.
Issue 2 — March 14, 2013
Read Dr Love’s original email (March 14, 2013)
HER2-Targeted Therapy and Chemotherapeutic Agents for HER2-Positive Advanced Breast Cancer
Program Description: A summary of research data evaluating existing and novel combinations of HER2-targeted antibodies and chemotherapy and a safety analysis of T-DM1 for HER2-positive advanced breast cancer.
Full Abstracts:
Confirmatory Overall Survival Analysis of CLEOPATRA
Swain SM et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: A randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2012; Abstract P5-18-26.
Biomarker Analyses in CLEOPATRA
Baselga J et al. Biomarker analyses in CLEOPATRA: A Phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2012; Abstract S5-1.
Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study
Miles D et al. Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. San Antonio Breast Cancer Symposium 2012; Abstract P5-18-01.
Phase II Study of Pertuzumab, Trastuzumab and Weekly Paclitaxel in HER2-Overexpressing Metastatic Breast Cancer
Datko F et al. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer. San Antonio Breast Cancer Symposium 2012;Abstract P5-18-20.
Phase IIIb PERUSE Study of Pertuzumab, Trastuzumab and a Taxane for HER2-Positive Advanced Breast Cancer
Bachelot T et al. A single-arm Phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE). San Antonio Breast Cancer Symposium 2012; Abstract OT1-1-02.
Pooled Safety Analysis of T-DM1 in HER2-Positive Metastatic Breast Cancer
Dieras V et al. Trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2-positive metastatic breast cancer: Pooled safety analysis. San Antonio Breast Cancer Symposium 2012; Abstract P5-18-06.
Phase II Study of Eribulin Mesylate and Trastuzumab for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Vahdat L et al. Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: Results from a Phase 2, multicenter, single-arm study. San Antonio Breast Cancer Symposium 2012;Abstract P5-20-04.
Issue 1 — February 8, 2013
Read Dr Love’s original email (February 8, 2013)
Endocrine Therapies for Estrogen Receptor-Positive Breast Cancer
Program Description: A summary of research data evaluating the optimal duration and role of combined endocrine therapy for pre- and postmenopausal patients with early or advanced breast cancer.
Full Abstracts:
ATLAS Trial of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years for Early Breast Cancer
Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012;[Epub ahead of print]. Abstract
A Phase II Study of Letrozole with or without PD 0332991 as First-Line Therapy for Advanced Breast Cancer
Finn RS et al. Results of a randomized Phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER-positive/HER2-negative advanced breast cancer. San Antonio Breast Cancer Symposium 2012; Abstract S1-6.
Final Overall Survival Analysis of CONFIRM Trial of 500 mg versus 250 mg of Fulvestrant
Di Leo A et al. Final analysis of overall survival for the Phase III CONFIRM trial: Fulvestrant 500 mg versus 250 mg. San Antonio Breast Cancer Symposium 2012; Abstract S1-4.
LEA Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer
Martin M et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer — First efficacy results from the LEA study. San Antonio Breast Cancer Symposium 2012; Abstract S1-7.
S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer
Chavez-MacGregor M et al. S1207: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2-neu negative breast cancer (NCT01674140). San Antonio Breast Cancer Symposium 2012; Abstract OT2-2-04.
|
